Spesolimab — Drug Intelligence | 6 EU Trials

Filter these 6 trials by condition, phase, country and more.

6 Registered trials

1 Recruiting

5 Completed trials

2 Sponsors

18 Countries

Phase III

Phase II/III

Phase II

Phase III/IV

Phase III: 1 Phase II/III: 3 Phase II: 1 Phase III/IV: 1

Oversight events:

12 temporary halts across 1 trial

Indications tested

6 total

A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Phase III 11 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A study to test whether spesolimab helps people with Generalized Pustular Psoriasis (GPP) who need treatment for repeated flares Ended

2022-502128-38-00 Phase III/IV 5 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou… Ended

2023-509216-28-00 Phase II 5 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Phase II/III 14 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended

2022-501074-19-00 Phase II/III 17 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended

2022-501104-10-00 Phase II/III 11 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…

Showing 1–6 of 6 trials